OptiNose Inc (OPTN) Quote

OPTN, new 52/low

OPTN........................https://stockcharts.com/h-sc/ui?s=OPTN&p=W&b=5&g=0&id=p86431144783

OPTN new 52 week low

OPTN under $2

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

OPTN 10Q due March 7

OPTN new 52 week low

nice volume

dip

OPTN
OPTINOSE INC
Last [Tick] $6.29[+]
Change Up $0.58
% Change Up 10.1576%

OPTN
5.87 [+] up tick
0.16 (2.8021%)

Press Release: Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
BY Dow Jones & Company, Inc.— 7:29 AM ET 08/04/2020

Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

Company reports second quarter 2020 XHANCE net revenue of $10.3 million

Second quarter 2020 XHANCE prescriptions increased 84% from second quarter 2019 (My emphasis- MG)

Conference call and webcast to be held today at 8:00 a.m. Eastern Time

YARDLEY, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Optinose ( OPTN ) , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2020, and provided operational updates.

"XHANCE prescription volume continued to grow in the second quarter, which was impressive given the major disruptions to patient volumes and care pathways within ENT and allergy physician practices," stated CEO Peter Miller. "XHANCE had exceptionally strong market share growth, demonstrating remarkable resilience, as we successfully adapted our business to the COVID-19 environment. We are excited by the potential for XHANCE to continue to grow and recently announced a co- promotion with kaléo that will amplify our effort. We look forward to a strong partnership that we believe can have meaningful impact."

OPTN 5.72 +12%

OPTN

AUG 04
OPTN to announce Q2 earnings (Confirmed)

It amazes me that a company like this, sitting on $140M in cash and a market cap of only $240M and a PT of $20 is going under the radar. Once the street gets word of it, SP will go to $15 which is its current market value TODAY.

OPTN Heading back up
Another Covid play.
I am looking for a breakout, here.
MG

OPTN Company website: https://www.optinose.com/

OPTN Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
BY GlobeNewswire — 4:15 PM ET 07/08/2020

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE® (fluticasone propionate) exhalation nasal spray 93 mcg, for the treatment of nasal polyps in patients 18 years or older in the United States.

"We are excited to partner with kaléo and leverage the strong relationships they have built with physicians in our target audience," said Vic Clavelli, Chief Commercial Officer of Optinose (OPTN). "This co-promotion partnership will build upon that strength and help us grow our target audience’s appreciation for all XHANCE has to offer by efficiently broadening and deepening our promotional reach. I am confident that the kaléo sales team will complement and amplify the efforts of the Optinose (OPTN) team starting in the fourth quarter of this year."

“Our team is pleased to collaborate with Optinose on the promotion of XHANCE,” said Omar Khalil, kaléo’s General Manager of Allergy and Pediatrics. “The deep relationships we have developed over the years with allergists makes kaléo a natural fit for this innovative product that serves the needs of patients with this condition.”

Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency. The audience includes nearly 6,000 prescribers about half of whom are outside of the current Optinose (OPTN) called-on universe of approximately 10,000 healthcare professionals.

About Optinose (OPTN)
Optinose ( OPTN ) is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

OPTN Ford Equity Research upgrades OPTINOSE INC from 4 to 3.
BY Investars Analyst Actions - 3:20 PM ET 07/10/2020

On July 10, 2020 Ford Equity Research upgraded OPTINOSE INC (OPTN ) from 4 to 3.

OPTN Refinitiv/Verus upgrades OPTINOSE INC from SELL to BUY.
BY Investars Analyst Actions - public— 3:01 PM ET 07/13/2020

On July 13, 2020 Refinitiv/Verus upgraded OPTINOSE INC (OPTN) from SELL to BUY.

OPTN Small cap ($275M) beginning study of its nasal spray for treatment of covid 19 in the sinus cavity, where the virus is thought to begin its passage.
Finances and share structure good. Anal rating and 'tute ownership good.
Two recent upgrades to BUY.
$19 PT Piper

MG

OPTN
OPTINOSE INC
6.238 Up 1.408 (29.1511 %) AS OF 11:36:42AM ET 07/17/2020

OPTI Just got in this morning @ 5.63
Currently 5.98
Nascent Covid 19 play

MG